Virological and Immunological Determinants of Arbovirus Infection in New Caledonia

Launched by INSTITUT PASTEUR · Nov 5, 2020

Keywords

ClinConnect Summary

This clinical trial is studying how certain viruses, known as arboviruses, cause infections like Zika, dengue, and chikungunya in New Caledonia. These viruses are spread to humans through mosquito bites, particularly from a mosquito called Aedes aegypti. The researchers aim to understand how the virus spreads and how the human immune system responds to these infections. They will do this by collecting blood samples from patients who show symptoms of an arbovirus infection, such as fever and muscle pain, within a week before the sample is taken.

To participate in the study, individuals must be adults experiencing symptoms suggestive of an arbovirus infection. They should not have other viral infections, be pregnant, or have recently traveled to certain areas. Participants will provide consent for their blood to be collected, which will help researchers learn more about how these viruses work and how the body fights them. This study is important for improving our understanding of arbovirus outbreaks and potentially guiding better prevention and treatment strategies in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Major patient
• * Patient with clinical signs suggestive of an arbovirus infection:
• • Fever And at least 2 clinical signs suggestive of arbovirus among which myalgia, retro-orbital pain, drop in platelets (if data available), digestive symptoms, etc.
• • Appearance of clinical signs suggestive of an arbovirus infection in the 7 days preceding the blood sample.
• • Patient informed of the performance of the research, the collection of data and biological samples
• • Patient who has given their consent to participate in the research by authorizing the collection of data, the collection of an additional blood sample and the use of this sample
• Exclusion Criteria:
• • Patient suffering from another identified virosis, an inflammatory disease or taking anti-inflammatory drugs
• • Pregnant patient
• • Patient returning from a trip within 15 days before the onset of the signs,
• • Patient for whom the blood sample is incomplete or could not be performed
• • Patient's condition, which, in the doctor's opinion, is incompatible with the additional sample required by the study
• • Patient not having consented to participate in the research